GR 55562 dihydrochloride
A selective competitive 5-HT1B (5-HT1Dβ) silent antagonist with pKB values of 7.3 and 6.3 for human cloned 5-HT1B and 5-HT1D receptors respectively and only weak binding at a number of other 5-HT subtypes.
Sold with the permission of GlaxoSmithKline
|Storage||Desiccate at +4°C|
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
Tocris products are intended for laboratory research use only, unless stated otherwise.
|Solubility||Soluble to 100 mM in water|
References are publications that support the biological activity of the product.
MacLean et al (1996) Evidence for 5-HT1-like receptor-mediated vasoconstriction in human pulmonary artery. Br.J.Pharmacol. 119 277 PMID: 8886409
Walsh et al (1995) The activity of 5-HT1D receptor ligands at cloned human 5-HT1Dα and 5-HT1Dβ receptors. Eur.J.Pharmacol. 287 79 PMID: 8666030
Connor et al (1995) Use of GR55562, a selective 5-HT1D antagonist, to investigate 5-HT1D receptor subtypes mediating cerebral vasoconstriction. Cephalalgia 15 99
If you know of a relevant reference for GR 55562 dihydrochloride, please let us know.
View Related Products by Product Action
Keywords: GR 55562 dihydrochloride, GR 55562 dihydrochloride supplier, 5-HT1B, antagonists, Serotonin, Receptors, GR55562, dihydrochloride, GlaxoSmithKline, GSK, 1054, Tocris Bioscience
7 Citations for GR 55562 dihydrochloride
Citations are publications that use Tocris products. Selected citations for GR 55562 dihydrochloride include:
Zhou et al (2019) Modulation of Kalirin-7 Expression by Hippocampal CA1 5-HT1B Receptors in Spatial Memory Consolidation. Behav Brain Res 356 148 PMID: 29949735
Müller et al (2009) 5-hydroxytryptamine modulates migration, cytokine and chemokine release and T-cell priming capacity of dendritic cells in vitro and in vivo. PLoS One 4 e6453 PMID: 19649285
McDaid and Docherty (2001) Vascular actions of MDMA involve alpha1 and alpha2-adrenoceptors in the anaesthetized rat. Br J Pharmacol 133 429 PMID: 11375260
Morecroft et al (2010) In vivo effects of a combined 5-HT1B receptor/SERT antagonist in experimental pulmonary hypertension. Exp Eye Res 85 593 PMID: 19736308
Johansson et al (2012) Expressional changes in cerebrovascular receptors after experimental transient forebrain ischemia. PLoS One 7 e41852 PMID: 22848635
Wei et al (2010) JNK regulates serotonin-mediated proliferation and migration of pulmonary artery smooth muscle cells. Am J Physiol Lung Cell Mol Physiol 298 L863 PMID: 20228179
Guo and Rainnie (2010) Presynaptic 5-HT(1B) receptor-mediated serotonergic inhibition of glutamate transmission in the bed nucleus of the stria terminalis. Neuroscience 165 1390 PMID: 19963045
Do you know of a great paper that uses GR 55562 dihydrochloride from Tocris? Please let us know.
Reviews for GR 55562 dihydrochloride
There are currently no reviews for this product. Be the first to review GR 55562 dihydrochloride and earn rewards!
Have you used GR 55562 dihydrochloride?
Submit a review and receive an Amazon gift card.
$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image
$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
Literature in this Area
Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* or download your copy today!
*Please note that Tocris will only send literature to established scientific business / institute addresses.
5-HT Receptors Scientific Review
Written by Nicholas M. Barnes and John F. Neumaier, this review summarizes the various serotonin receptor subtypes and their importance in mediating the role of serotonin in numerous physiological and pharmacological processes. Compounds available from Tocris are listed.
Parkinson's disease (PD) causes chronic disability and is the second most common neurodegenerative condition. This poster outlines the neurobiology of the disease, as well as highlighting current therapeutic treatments for symptomatic PD, and emerging therapeutic strategies to delay PD onset and progression.